Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59

被引:76
作者
Ziller, F
Macor, P
Bulla, R
Sblattero, D
Marzari, R
Tedesco, F
机构
[1] Univ Trieste, Dept Physiol & Pathol, I-34127 Trieste, Italy
[2] Univ Trieste, Dept Biol, I-34127 Trieste, Italy
关键词
human monoclonal antibody; complement; complement regulatory proteins; lymphoma cell lines; rituximab;
D O I
10.1002/eji.200425920
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Expression of the complement-regulatory proteins (CRP) CD46, CD55 and CD59 represents a strategy used by tumor cells to evade complement-dependent cell cytoxicity stimulated by monoclonal antibodies. We have isolated two single-chain variable fragments (scFv) to CD55 and CD59 from a human phage-display library and from these scFv we have produced two miniantibodies (MB), MB-55 (against CD55) and MB-59 (against CD59), containing the human hinge-CH2-CH3 domains of IgG1. The specificity of the two MB for the corresponding CRP was assessed by ELISA using purified CD46, CD55 and CD59. MB-55 and MB-59 neutralized the inhibitory activity of CD55 and CD59, respectively, restoring the complement-mediated lysis of sheep and guinea pig erythrocytes that was otherwise inhibited by the two CRP. FACS analysis revealed binding of MB-55 and MB-59 to the lymphoma cell line Karpas 422. The two MB induced a two-fold increase in the complement-dependent killing of these cells stimulated by Rituximab, a chimeric anti-CD20 monoclonal antibody. Transfection of HEK293T cells with vectors encoding MB-55 or MB-59 markedly reduced the expression of CD55 and CD59. We conclude that the human antibodies MB-55 and MB-59 may represent a therapeutic tool to increase the complement-dependent killing activity of Rituximab in the treatment of non-Hodgkin's lymphoma.
引用
收藏
页码:2175 / 2183
页数:9
相关论文
共 39 条
[1]   Generating improved single-chain Fv molecules for tumor targeting [J].
Adams, GP ;
Schier, R .
JOURNAL OF IMMUNOLOGICAL METHODS, 1999, 231 (1-2) :249-260
[2]   EXPRESSION OF HUMAN B CELL-ASSOCIATED ANTIGENS ON LEUKEMIAS AND LYMPHOMAS - A MODEL OF HUMAN B-CELL DIFFERENTIATION [J].
ANDERSON, KC ;
BATES, MP ;
SLAUGHENHOUPT, BL ;
PINKUS, GS ;
SCHLOSSMAN, SF ;
NADLER, LM .
BLOOD, 1984, 63 (06) :1424-1433
[3]   Decline of surface MHC I by adenoviral gene transfer of anti-MHC I intrabodies in human endothelial cells - new perspectives for the generation of universal donor cells for tissue transplantation [J].
Beyer, F ;
Doebis, C ;
Busch, A ;
Ritter, T ;
Mhashilkar, A ;
Marasco, WM ;
Laube, H ;
Volk, HD ;
Seifert, M .
JOURNAL OF GENE MEDICINE, 2004, 6 (06) :616-623
[4]   ACTIVATION OF ALTERNATIVE COMPLEMENT PATHWAY BY LYMPHOBLASTOID CELL LINES DERIVED FROM PATIENTS WITH BURKITTS-LYMPHOMA AND INFECTIOUS-MONONUCLEOSIS [J].
BUDZKO, DB ;
LACHMANN, PJ ;
MCCONNELL, I .
CELLULAR IMMUNOLOGY, 1976, 22 (01) :98-109
[5]   Intracerebroventricular injection of the terminal complement complex causes inflammatory reaction in the rat brain [J].
Casarsa, C ;
De Luigi, A ;
Pausa, M ;
De Simoni, MG ;
Tedesco, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (05) :1260-1270
[6]   Complement activation determines the therapeutic activity of rituximab in vivo [J].
Di Gaetano, N ;
Cittera, E ;
Nota, R ;
Vecchi, A ;
Grieco, V ;
Scanziani, E ;
Botto, M ;
Introna, M ;
Golay, J .
JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1581-1587
[7]   Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies [J].
Figini, M ;
Ferri, R ;
Mezzanzanica, D ;
Bagnoli, M ;
Luison, E ;
Miotti, S ;
Canevari, S .
GENE THERAPY, 2003, 10 (12) :1018-1025
[8]   MEASUREMENTS OF THE TRUE AFFINITY CONSTANT IN SOLUTION OF ANTIGEN-ANTIBODY COMPLEXES BY ENZYME-LINKED IMMUNOSORBENT-ASSAY [J].
FRIGUET, B ;
CHAFFOTTE, AF ;
DJAVADIOHANIANCE, L ;
GOLDBERG, ME .
JOURNAL OF IMMUNOLOGICAL METHODS, 1985, 77 (02) :305-319
[9]   MANNOSE-BINDING PROTEIN RECOGNIZES GLIOMA-CELLS - IN-VITRO ANALYSIS OF COMPLEMENT ACTIVATION ON GLIOMA-CELLS VIA THE LECTIN PATHWAY [J].
FUJITA, T ;
TAIRA, S ;
KODAMA, N ;
MATSUSHITA, M ;
FUJITA, T .
JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (02) :187-192
[10]   SYNTHESIS OF C3, C5, C6, C7, C8, AND C9 BY HUMAN FIBROBLASTS [J].
GARRED, P ;
HETLAND, G ;
MOLLNES, TE ;
STOERVOLD, G .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1990, 32 (05) :555-560